Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →AbbVie has cleared the way for its $63 billion acquisition of Allergan with two divestitures negotiated with the FTC. AstraZeneca will reclaim brazikumab, an…
Nestle Health Science separately agreed to acquire Allergan's gastrointestinal therapies Zenpep and Viokace, the companies said in announcing two divestitures…
Nestle Health Science announced the close (May 11, 2020) of its acquisition of Zenpep and Viokace from Allergan. The release explicitly states 'Financial…
Source summaries from our enrichment pipeline; follow links for originals.
All 9 sources with sentiment breakdown →
As part of FTC clearance for AbbVie's Allergan acquisition, Allergan divested pancreatic enzyme replacement therapies Zenpep and Viokace to Nestle Health Science. Terms not disclosed; deal completed alongside AbbVie/Allergan close.
Assessment window: 5yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Nestle S.A. / Allergan plc (this deal) | 2020 | — | — |
| Nestle S.A. / Aimmune Therapeutics, Inc. | 2020 | $2.6B | — |
| UCB SA / Celltech Group plc | 2004 | $2.7B | 92 |
| Johnson & Johnson / Centocor Inc. | 1999 | $4.9B | 92 |
| Takeda Pharmaceutical Company Ltd. / Millennium Pharmaceuticals | 2003 | $8.8B | 82 |
| Bristol-Myers Squibb Company / Celgene Corporation | 2019 | $74.0B | 77 |
| Biogen Idec Inc. / Elan Corporation plc (Tysabri rights) | 2013 | $3.2B | 77 |
← Browse all deals · How we score deals
More: 2020 deals · Gastroenterology deals